Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity

Cancer Research

Volumn 66, Issue 13, 2006, Pages 6503-6511

  Petti, Carlotta ^a   Molla, Alessandra ^a   Vegetti, Claudia ^a   Ferrone, Soldano ^b   Anichini, Andrea ^a   Sensi, Marialuisa ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; HLA ANTIGEN CLASS 1; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; BRAF PROTEIN, HUMAN; DOXYCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE B; PROTEIN P21;

ARTICLE; BRAF ONCOGENE; CELL CLONE; CELL CYCLE PHASE; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; METASTASIS; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE N RAS; PRIORITY JOURNAL; SENESCENCE; SIGNAL TRANSDUCTION; UPREGULATION; ALLELE; ANTIGEN PRESENTATION; BIOSYNTHESIS; CELL AGING; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ALLELES; ANTIGEN PRESENTATION; CELL AGING; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DOXYCYCLINE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); T-LYMPHOCYTES, CYTOTOXIC;

EID: 33746162101     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4671     Document Type: Article

References (54)

1. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
3. Gray-Schopfer VC, da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 2005;24:165-83.
4. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
5. Feng YZ, Shiozawa T, Miyamoto T, et al. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res 2005;11:6133-8.
6. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-6.
7. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005;24:6646-56.
8. Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 2003;22:9217-24.
9. Akslen LA, Angelini S, Straume O, et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 2005;125:312-7.
10. V600EBRAF mutations at single cell level in the same human melanoma. Oncogene advance online publication: doi: 10.1038/sj.onc.1209379 2006.
11. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NHAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006;126:154-60.
12. Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98.
13. Anichini A, Mazzocchi A, Fossati G, Parmiani G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J Immunol 1989;142:3692-701.
14. Daniotti M, Oggionni M, Ranzani T, et al. B-RAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 2004;23:5968-77.
15. Johnson KY, Liu L, Vincent TS. Minimal FLAG sequence useful in the functional epitope tagging of H-Ras. Biotechniques 2002;32:1270-80.
16. Zanon M, Piris A, Bersani I, et al. Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res 2004;64:7386-94.
17. de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 1997;14:623-5.
18. Maccalli C, Pisarra P, Vegetti C, Sensi M, Parmiani G, Anichini A. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. J Immunol 1999;163:6912-23.
19. Bandoh N, Ogino T, Cho HS, et al. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 2005;66:185-94.
20. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 2003;62:385-93.
21. Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 1983;130:2471-8.
22. Parham P, Barnstable CJ, Bodmer WF. Use of monoclonal antibody (W6/32) in structural studies of HLA-A, -B, -C antigens. J Immunol 1979;123:536-45.
23. Anichini A, Molla A, Mortarini R, et al. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 1999;190:651-67.
24. Maellaro E, Dominici S, Del Bello B, et al. Membrane gamma-glutamyl transpeptidase activity of melanoma cells: effects on cellular H(2)O(2) production, cell surface protein thiol oxidation and NF-kappa B activation status. J Cell Sci 2000;113:2671-8.
25. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
26. Albini A. Tumor and endothelial cell invasion of basement membranes. The Matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res 1998;4:230-41.
27. Fridman R, Kibbey MC, Royce LS, et al. Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel. J Natl Cancer Inst 1991;83:769-74.
28. Campisi J. Senescent cells, tumour suppression, and organismal aging: good citizens, bad neighbors. Cell 2005;120:513-22.
29. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004;23:2919-33.
30. Hardie DG. New roles for the LKB1->AMPK pathway. Curr Opin Cell Biol 2005;17:167-73.
31. Wang W, Yang X, Lopez de Silanes I, Carling D, Gorospe M. Increased AMP:ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function. J Biol Chem 2003;278:27016-23.
32. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004;321:161-7.
33. Chang BD, Watanabe K, Broude EV, et al. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci U S A 2000;97:4291-6.
34. Dunn GP, Bruce AT, lkeda H, Old L, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
35. + T cells in melanoma patients receiving interleukin 12. Cancer Res 2000;60:3559-68.
36. Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000;60:1800-4.
37. Pavey S, Johansson P, Packer L, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004;23:4060-7.
38. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62.
39. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 2005;37:745-9.
40. 599EB-RAF is an oncogene in melanocytes. Cancer Res 2004;64:2338-42.
41. E600- associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4.
42. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
43. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
44. Sewing A, Wiseman B, Lloyd AC, Land H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 1997;17:5588-97.
45. Lin AW, Barradas M, Stone JC, Van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998;12:3008-19.
46. Passioura T, Dolnikov A, Shen S, Symonds G. N-ras-induced growth suppression of myeloid cells is mediated by IRF-1. Cancer Res 2005;65:797-804.
47. Lodygin D, Menssen A, Hermeking H. Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest 2002;110:1717-27.
48. Steingrimsson E, Copeland NG, Jenkins NA. Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet 2004;38:365-411.
49. Carreira S, Goodall J, Aksan I, et al. Mitf cooperates with Rbl and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005;433:764-9.
50. Vance KW, Carreira S, Brosch G, Coding CR. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res 2005;65:2260-8.
51. Wellbrock C, Marais R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 2005;170:703-8.
52. Salti GJ, Manougian T, Farolan M, Shilkaitis A, Majumdar D, Das Gupta TK. Micropthalmia transcription factor; a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 2000;60:5012-6.
53. Widlund HR, Fisher DE. Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 2003;22:3035-41.
54. Lehner PJ, Cresswell P. Recent developments in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004;16:82-9.